I projektet udvikles en hybrid pasteuriseringsløsning og robotgribeløsning, der muliggør en hurtig og fleksibel tappeløsning til drikkevarer uden egenkonservering og med komplekse proteinstrenge. Løsningen vil kunne levere samme renhed som langt dyrere og langsommere autoklaveløsninger, samt en avanceret sensorpakke der muliggør automatiseret dokumentation af alle delprocesser i produktionen. Løsningen vil også muliggøre rentabel produktion af selv meget små højkvalitetsproduktserier.

Daglig motion er vigtig når man kommer op i alderen. 30 minutter daglig motion øger chancen for et længere liv med højere livskvalitet – men mange følger ikke anbefalingerne. 4Mvideo er et videobaseret cykelmotionssystem til seniorer (se film www.4mvideo.dk), som øger motivation og muligheder for motion. Det består af et website med cykelvideoer og en 4Mvideo-app, der installeret på en tablet-computer, kan afspille cykelvideoer i takt med pedaltrådet på motionscykel med påmonteret kadancesensor.

Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than one in five cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals. We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.

Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than 1 in 5 cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals. We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.

The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. IBD is a disease entity of unknown origin, characterized by a chronic inflammation in the gastrointestinal tract. IBD is increasing, especially among teenagers, and today 0.5-1% of the Nordic population is affected. The disease course varies from an indolent course to an aggressive, treatment refractory disease, with need of repeated hospital admissions, surgery and increased risk of comorbidity including cancer. Thus, IBD have severe consequences for many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves, and surgic

The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. In this project, our aim is to selectively identify patients with a poor prognosis based on a novel objective protein signature, recently identified by members of the NORDTREAT team, and adapt the treatment in these patients to minimize disease-induced damage on the gastrointestinal tract and to improve longterm disease outcomes. NORDTREAT exploitation plan includes the development of this protein signature into a diagnostic application, implementation of this diagnostic application as a prognostic tool in healthcare and exploration of potential biomarkers.

The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. IBD is a disease entity of unknown origin, characterized by a chronic inflammation in the gastrointestinal tract. IBD is increasing, especially among teenagers, and today 0.5-1% of the Nordic population is affected. The disease course varies from an indolent course to an aggressive, treatment refractory disease, with need of repeated hospital admissions, surgery and increased risk of comorbidity including cancer. Thus, IBD have severe consequences for many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves,

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces lifeexpectance. Many disease mechanisms and risk factors are known in IHD, but we need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm.

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm

The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases, specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients. Personalized medicine is a neglected, albeit much desired, development in the field of acute infectious diseases. The patient population is highly heterogeneous with different pathogens, pathogenic mechanisms, as well as varying predisposing host factors, and importantly, a dysregulated host response to infection is directly linked to severity and outcome of severe infections, i.e. sepsis and NSTI. PERAID builds on the advances and resources created in the EU FP7-project INFECT, including the worlds largest patient cohort on NSTI (Scandinavian patients enrolled by PERAIDs partners from Denmark, Norway and Sweden), biobank, multi-omics data, and pathophysiologic models.

Please see upload Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality. RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too late, despite the increasing number of different, and still expensive, medicines that have become available in rout

Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality. RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too late, despite the increasing number of different, and still expensive, medicines that have become available in routine care. ...